Baricitinib is an inhibitor of JAK1/JAK2 and has been FDA-approved for the treatment of rheumatoid arthritis. Although it has both antiviral and anti-inflammatory activity, it has been noted for its potential deleterious effects since it has inhibitory effects on an interferon-mediated antiviral response and has a potential risk of thromboembolism. These potential hazards should be considered when weighing options for treatment.